Last updated: February 9, 2026
Overview
Amprenavir, marketed as Agenerase, is an HIV protease inhibitor developed by GlaxoSmithKline (GSK). It received FDA approval in November 1999. The drug was innovated to improve upon existing protease inhibitors by increasing potency and reducing adverse effects. However, it was later superseded by newer agents with better efficacy and safety profiles.
Market Position and Evolution
- Initial Market Impact: Amprenavir was positioned as a second-generation protease inhibitor, intended for treatment-experienced HIV patients.
- Market Decline: By 2004, GSK phased out amprenavir, replacing it with fosamprenavir, its prodrug with improved pharmacokinetics and diminished dosing frequency.
- Patent Status: U.S. patent protection lasted until approximately 2007–2008. After expiry, generic competition emerged, eroding market share.
- Current Market Standing: Amprenavir is no longer marketed; its shares are negligible or non-existent. Its primary relevance now is in historical patent and drug development data.
Patent and Intellectual Property Landscape
- Patent Timeline: The key patent for amprenavir was filed in the late 1990s, expiring in the late 2000s.
- Generic Competition: Post-patent expiry, generic manufacturers produced equivalent formulations, reducing GSK’s revenue and market exclusivity.
- Implications: Proprietary rights on amprenavir are virtually null, limiting investment or development prospects related to the original molecule.
Development and Regulatory Pathways
- Initial Approval: The FDA granted approval based on Phase III clinical trial data showing efficacy in reducing viral load.
- Regulatory Status: Withdrawn from the market; no recent approvals or INDs relate to amprenavir.
- Reformulation Potential: No current active development or reformulation efforts are publicly known, owing to market obsolescence.
Financial and Corporate Considerations
- Revenue Impact: GSK’s HIV portfolio shifted focus from amprenavir to newer agents like dolutegravir and darunavir.
- Market Trends: The HIV treatment market increasingly favors drugs with better safety and dosing profiles, limiting relevance of older agents.
- Investment Outlook: Limited. The molecule is obsolete for commercial development; primary value lies in historical patent analysis and understanding drug evolution.
Potential Future Opportunities
- Research Use: The compound’s structure may serve as a starting point for new protease inhibitors with different targets or mechanisms.
- Patent Fundamentals: While the original patent has expired, derivative patents could be filed if novel modifications are developed.
- Data Utilization: Data from past trials are useful for academic or bioinformatics research but offer minimal commercial investment appeal.
Key Points Summary
- Amprenavir was approved in 1999, discontinued by GSK circa 2004.
- Patent protection ended around 2007–2008.
- The drug is obsolete; no current development or commercialization.
- Investment prospects are limited to potential research or patenting new derivatives.
- The market has shifted toward drugs with improved safety, convenience, and efficacy.
Key Takeaways
- Market Revocation: Amprenavir has no current commercial or regulatory relevance.
- Patent Life Cycle: Its patents have expired, facilitating generics.
- Development Prospects: Near-zero prospects for reformulation or new development.
- Historical Data Value: Useful in patent landscape analysis but not as an active investment.
- Strategic Focus: Companies should monitor newer protease inhibitors and HIV agents for current investment opportunities.
FAQs
1. Why is amprenavir no longer available for sale?
It was discontinued by GSK around 2004 due to the advent of newer HIV protease inhibitors with improved profiles.
2. Does the patent of amprenavir still provide exclusivity?
No. The patent expired around 2007–2008, allowing generic versions to enter the market.
3. Can the structure of amprenavir be used to develop new drugs?
Yes. Its chemical scaffold can serve as a basis for designing new protease inhibitors, provided modifications meet regulatory standards.
4. What are the main factors undermining amprenavir’s market value now?
Marketed drugs have superior efficacy, safety, dosing, and formulations, making amprenavir obsolete.
5. Are there any ongoing trials or research involving amprenavir?
No. Current activity centers on research uses or derivative patent filings, not clinical trials involving the original drug.
Citations
[1] U.S. Food and Drug Administration. Agenerase (Amprenavir) Approval History.
[2] GlaxoSmithKline. HIV portfolio updates, 2004–2008.
[3] PatentScope. Patent information on amprenavir-related patents.
